Disease · MONDO_0000088

precocious puberty

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. precocious puberty. Diseases, record MONDO_0000088. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000088

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: precocious puberty; Open Targets
Open Targets ID: MONDO_0000088; Open Targets
Other names: pubertas praecox, sexual precocity; Open Targets
MeSH: D011629; MeSH
NCI Thesaurus: C79704; NCI Thesaurus
Orphanet: ORPHA:95708; Orphanet
Highest stage of its drugs: Approval, for 2 of its 12 drugs, from DailyMed; Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LEUPROLIDE ACETATE	CHEMBL1200775	Protein	Approval	DailyMed	6	5	5	Drugs and targets
TRIPTORELIN PAMOATE	CHEMBL1200554	Protein	Approval	DailyMed	1	0	0	Drugs and targets
TRIPTORELIN	CHEMBL1201334	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
LEUPROLIDE	CHEMBL1201199	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ANASTROZOLE	CHEMBL1399	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BICALUTAMIDE	CHEMBL409	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DESLORELIN	CHEMBL2365665	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
FULVESTRANT	CHEMBL1358	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TESTOLACTONE	CHEMBL1571	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LETROZOLE	CHEMBL1444	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets55

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GNRHR	Gonadotropin-releasing hormone receptor	5	Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor antagonist	Approval	https://conductscience.org/library/genes/2798	Drugs and targets
CYP19A1	Aromatase	3	Cytochrome P450 19A1 inhibitor	Phase 2	https://conductscience.org/library/genes/1588	Drugs and targets
AR	Androgen receptor	1	Androgen Receptor antagonist	Phase 2	https://conductscience.org/library/genes/367	Drugs and targets
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Unknown	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Unknown	https://conductscience.org/library/genes/56901	Drugs and targets
ESR1	Estrogen receptor	1	Estrogen receptor alpha antagonist; Estrogen receptor degrader	Phase 2	https://conductscience.org/library/genes/2099	Drugs and targets
GPD2	Glycerol-3-phosphate dehydrogenase, mitochondrial	1	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor	Unknown	https://conductscience.org/library/genes/2820	Drugs and targets
MT-ND1	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Unknown	https://conductscience.org/library/genes/4535	Drugs and targets
MT-ND2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Unknown	https://conductscience.org/library/genes/4536	Drugs and targets
MT-ND3	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Unknown	https://conductscience.org/library/genes/4537	Drugs and targets

1 to 10 of 55

See all 55 targets

Trials14

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02452931	Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty	Phase 3	64	2020-05-20	Precocious Puberty, Central	LEUPROLIDE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT00564850	Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty	Phase 3	37	2011-12-01	Precocious Puberty	TRIPTORELIN	Its record names the disease	ClinicalTrials.gov
NCT00909844	Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study	Phase 3	35	2017-05-01	Precocious Puberty	TRIPTORELIN	Its record names the disease	ClinicalTrials.gov
NCT00278915	Faslodex in McCune-Albright Syndrome	Phase 2	30	2011-07-19	Puberty, Precocious, McCune-Albright Syndrome	FULVESTRANT	Its record names the disease	ClinicalTrials.gov
NCT00094328	Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]	Phase 2	14	2009-07-09	Puberty, Precocious	ANASTROZOLE, BICALUTAMIDE	Its record names the disease	ClinicalTrials.gov
NCT05957991	Danish Precocious Puberty Study - DAPP Study A National Cohort Study on Incidence and Etiologies for Precocious Puberty		1,500		Puberty, Precocious	METFORMIN HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00001181	Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty	Phase 2	100		Polyostotic Fibrous Dysplasia, Precocious Puberty	TESTOLACTONE	Its record names the disease	ClinicalTrials.gov
NCT06025409	Evaluate the Efficacy and Safety of DWJ108J	Phase 3	79		Central Precocious Puberty	LEUPROLIDE, LEUPROLIDE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT01634321	The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty	Phase 4	63		Central Precocious Puberty	LEUPROLIDE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT00001190	Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature	Phase 2	50		Dwarfism, Growth Disorder	DESLORELIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 14

See all 14 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32738042	DERIVED	1	PubMed
22999294	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000088

GET https://conductscience.org/api/diseases/v1/MONDO_0000088/targets?page=2

API reference For AI assistants